Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
T-Cure Bioscience Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This volume of active prosecution indicates a focused patent strategy. The portfolio is distributed across 2 distinct examiners, which means each of the 2 pending office actions is being reviewed by a different individual at the USPTO.
The prosecution activity is spread across 2 distinct art units. This suggests that the company's technology spans multiple specialized classifications within the biotechnology sector. For the practitioner, this distribution requires a strategy that accounts for the specific examination standards of each of the 2 distinct art units.
LEE, YIE CHIA is the busiest examiner for the portfolio, currently handling 1 busiest examiner pending action. While LEE, YIE CHIA is the most active examiner, the workload is evenly split among the 2 distinct examiners involved. Understanding the specific preferences of LEE, YIE CHIA is essential for advancing the matters under their review.
With 2 pending office actions, the company's prosecution environment is balanced. Practitioners should ensure that arguments remain consistent across the different examiners while addressing the unique technical requirements of the Biotechnology & Pharmaceuticals area. This approach will help in navigating the complexities of the USPTO's review process.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550006 | METHODS OF ENHANCING DIVERSITY OF HLA HAPLOTYPE EXPRESSION IN TUMORS TO BROADEN TUMOR CELL SUSCEPTIBILITY TO TCR-T THERAPY | LEE, YIE CHIA | 8d overdue |
| 18250347 | RECOMBINANT T-CELL RECEPTORS THAT BIND THE NY-ESO-1 AND/OR LAGE-1A CANCER ANTIGENS | BRISTOL, LYNN ANNE | 28d |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18550006 | METHODS OF ENHANCING DIVERSITY OF HLA HAPLOTYPE EXPRESSION IN TUMORS TO BROADEN TUMOR CELL SUSCEPTIBILITY TO TCR-T THERAPY | LEE, YIE CHIA | 1642 | §112 | Final Rejection | 8d overdue | Pending | Sep 11, 2023 |
| 18250347 | RECOMBINANT T-CELL RECEPTORS THAT BIND THE NY-ESO-1 AND/OR LAGE-1A CANCER ANTIGENS | BRISTOL, LYNN ANNE | 1643 | §112Other | Final Rejection | 28d | Pending | Apr 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial